<?xml version='1.0' encoding='utf-8'?>
<document id="27853934"><sentence text="Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone."><entity charOffset="92-99" id="DDI-PubMed.27853934.s1.e0" text="N-Oxide" /><entity charOffset="131-140" id="DDI-PubMed.27853934.s1.e1" text="Clozapine" /><entity charOffset="142-154" id="DDI-PubMed.27853934.s1.e2" text="Levofloxacin" /><entity charOffset="156-167" id="DDI-PubMed.27853934.s1.e3" text="Roflumilast" /><entity charOffset="169-181" id="DDI-PubMed.27853934.s1.e4" text="Voriconazole" /><entity charOffset="186-195" id="DDI-PubMed.27853934.s1.e5" text="Zopiclone" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e0" e2="DDI-PubMed.27853934.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e0" e2="DDI-PubMed.27853934.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e0" e2="DDI-PubMed.27853934.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e0" e2="DDI-PubMed.27853934.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e0" e2="DDI-PubMed.27853934.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e0" e2="DDI-PubMed.27853934.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e1" e2="DDI-PubMed.27853934.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e1" e2="DDI-PubMed.27853934.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e1" e2="DDI-PubMed.27853934.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e1" e2="DDI-PubMed.27853934.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e1" e2="DDI-PubMed.27853934.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e2" e2="DDI-PubMed.27853934.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e2" e2="DDI-PubMed.27853934.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e2" e2="DDI-PubMed.27853934.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e2" e2="DDI-PubMed.27853934.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e3" e2="DDI-PubMed.27853934.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e3" e2="DDI-PubMed.27853934.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e3" e2="DDI-PubMed.27853934.s1.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e4" e2="DDI-PubMed.27853934.s1.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s1.e4" e2="DDI-PubMed.27853934.s1.e5" /></sentence><sentence text="The role of metabolite(s) to elicit potential clinical drug-drug interaction (DDI) via cytochrome P450 enzymes (CYP) is gaining momentum" /><sentence text=" In this context, the role of N-oxides for in vitro CYP inhibition has not been evaluated"><entity charOffset="30-38" id="DDI-PubMed.27853934.s3.e0" text="N-oxides" /></sentence><sentence text=" The objectives of this study were: (a) to examine in vitro CYP inhibition of N-oxides of clozapine, levofloxacin, roflumilast, voriconazole and zopiclone in a tiered approach and (b) evaluate in vitro fate of aforementioned N-oxides examined in recombinant CYPs, human microsomes and hepatocytes"><entity charOffset="78-86" id="DDI-PubMed.27853934.s4.e0" text="N-oxides" /><entity charOffset="90-99" id="DDI-PubMed.27853934.s4.e1" text="clozapine" /><entity charOffset="101-113" id="DDI-PubMed.27853934.s4.e2" text="levofloxacin" /><entity charOffset="115-126" id="DDI-PubMed.27853934.s4.e3" text="roflumilast" /><entity charOffset="128-140" id="DDI-PubMed.27853934.s4.e4" text="voriconazole" /><entity charOffset="145-154" id="DDI-PubMed.27853934.s4.e5" text="zopiclone" /><entity charOffset="225-233" id="DDI-PubMed.27853934.s4.e6" text="N-oxides" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e0" e2="DDI-PubMed.27853934.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e1" e2="DDI-PubMed.27853934.s4.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e1" e2="DDI-PubMed.27853934.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e1" e2="DDI-PubMed.27853934.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e1" e2="DDI-PubMed.27853934.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e1" e2="DDI-PubMed.27853934.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e1" e2="DDI-PubMed.27853934.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e2" e2="DDI-PubMed.27853934.s4.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e2" e2="DDI-PubMed.27853934.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e2" e2="DDI-PubMed.27853934.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e2" e2="DDI-PubMed.27853934.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e2" e2="DDI-PubMed.27853934.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e3" e2="DDI-PubMed.27853934.s4.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e3" e2="DDI-PubMed.27853934.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e3" e2="DDI-PubMed.27853934.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e3" e2="DDI-PubMed.27853934.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e4" e2="DDI-PubMed.27853934.s4.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e4" e2="DDI-PubMed.27853934.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e4" e2="DDI-PubMed.27853934.s4.e6" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e5" e2="DDI-PubMed.27853934.s4.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s4.e5" e2="DDI-PubMed.27853934.s4.e6" /></sentence><sentence text="" /><sentence text="CYP enzymes evaluated in the work included: CYP1A2, 2B6, 2C9, 2C19, 2D6 and 3A4 using standard procedures for incubation with appropriate probe substrates" /><sentence text=" The initial cutoff for CYP inhibition was ≥50% using 2 and 10 µM concentrations of various N-oxide metabolites (Tier 1)"><entity charOffset="92-99" id="DDI-PubMed.27853934.s7.e0" text="N-oxide" /></sentence><sentence text=" IC50 values were constructed for the CYP pathway(s) that showed ≥50% inhibition (Tier 2)" /><sentence text=" In addition, co-incubation of N-oxides with parent was performed to evaluate potentiation of CYP inhibition (Tier 3)"><entity charOffset="31-39" id="DDI-PubMed.27853934.s9.e0" text="N-oxides" /></sentence><sentence text="" /><sentence text="N-oxides of clozapine (CYP2B6/2C19) and voriconazole (CYP2C9/3A4) showed CYP inhibition ≥50%"><entity charOffset="0-8" id="DDI-PubMed.27853934.s11.e0" text="N-oxides" /><entity charOffset="12-21" id="DDI-PubMed.27853934.s11.e1" text="clozapine" /><entity charOffset="23-29" id="DDI-PubMed.27853934.s11.e2" text="CYP2B6" /><entity charOffset="30-34" id="DDI-PubMed.27853934.s11.e3" text="2C19" /><entity charOffset="40-52" id="DDI-PubMed.27853934.s11.e4" text="voriconazole" /><entity charOffset="54-60" id="DDI-PubMed.27853934.s11.e5" text="CYP2C9" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e0" e2="DDI-PubMed.27853934.s11.e0" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e0" e2="DDI-PubMed.27853934.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e0" e2="DDI-PubMed.27853934.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e0" e2="DDI-PubMed.27853934.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e0" e2="DDI-PubMed.27853934.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e0" e2="DDI-PubMed.27853934.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e1" e2="DDI-PubMed.27853934.s11.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e1" e2="DDI-PubMed.27853934.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e1" e2="DDI-PubMed.27853934.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e1" e2="DDI-PubMed.27853934.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e1" e2="DDI-PubMed.27853934.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e2" e2="DDI-PubMed.27853934.s11.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e2" e2="DDI-PubMed.27853934.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e2" e2="DDI-PubMed.27853934.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e2" e2="DDI-PubMed.27853934.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e3" e2="DDI-PubMed.27853934.s11.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e3" e2="DDI-PubMed.27853934.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e3" e2="DDI-PubMed.27853934.s11.e5" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e4" e2="DDI-PubMed.27853934.s11.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s11.e4" e2="DDI-PubMed.27853934.s11.e5" /></sentence><sentence text=" Clozapine-N-oxide inhibited CYP2B6 and CYP2C19 pathways with IC50 of 8"><entity charOffset="1-18" id="DDI-PubMed.27853934.s12.e0" text="Clozapine-N-oxide" /><entity charOffset="43-59" id="DDI-PubMed.27853934.s12.e1" text="2C19" /><pair ddi="false" e1="DDI-PubMed.27853934.s12.e0" e2="DDI-PubMed.27853934.s12.e0" /><pair ddi="false" e1="DDI-PubMed.27853934.s12.e0" e2="DDI-PubMed.27853934.s12.e1" /></sentence><sentence text="3 and 8" /><sentence text="7 µM, respectively" /><sentence text=" Voriconazole-N-oxide inhibited CYP2B6 and CYP2C19 pathways with IC50 of 10"><entity charOffset="1-21" id="DDI-PubMed.27853934.s15.e0" text="Voriconazole-N-oxide" /><entity charOffset="46-65" id="DDI-PubMed.27853934.s15.e1" text="2C19" /><pair ddi="false" e1="DDI-PubMed.27853934.s15.e0" e2="DDI-PubMed.27853934.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27853934.s15.e0" e2="DDI-PubMed.27853934.s15.e1" /></sentence><sentence text="5 and 11" /><sentence text="2 µM, respectively" /><sentence text=" Co-incubation of clozapine-N-oxide with clozapine potentiated CYP2B6/2C19 pathways; however, incubation of voriconazole-N-oxide with voriconazole did not appear to potentiate the CYP pathways because parent caused an inhibition of almost 80%"><entity charOffset="18-35" id="DDI-PubMed.27853934.s18.e0" text="clozapine-N-oxide" /><entity charOffset="41-50" id="DDI-PubMed.27853934.s18.e1" text="clozapine" /><entity charOffset="108-128" id="DDI-PubMed.27853934.s18.e2" text="voriconazole-N-oxide" /><entity charOffset="134-146" id="DDI-PubMed.27853934.s18.e3" text="voriconazole" /><entity charOffset="70-81" id="DDI-PubMed.27853934.s18.e4" text="2C19" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e0" e2="DDI-PubMed.27853934.s18.e0" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e0" e2="DDI-PubMed.27853934.s18.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e0" e2="DDI-PubMed.27853934.s18.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e0" e2="DDI-PubMed.27853934.s18.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e0" e2="DDI-PubMed.27853934.s18.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e1" e2="DDI-PubMed.27853934.s18.e1" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e1" e2="DDI-PubMed.27853934.s18.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e1" e2="DDI-PubMed.27853934.s18.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e1" e2="DDI-PubMed.27853934.s18.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e4" e2="DDI-PubMed.27853934.s18.e4" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e4" e2="DDI-PubMed.27853934.s18.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e4" e2="DDI-PubMed.27853934.s18.e3" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e2" e2="DDI-PubMed.27853934.s18.e2" /><pair ddi="false" e1="DDI-PubMed.27853934.s18.e2" e2="DDI-PubMed.27853934.s18.e3" /></sentence><sentence text=" None of the N-oxides appeared to further undergo biotransformation as judged by the in vitro metabolic fate experiments (stage 2)"><entity charOffset="13-21" id="DDI-PubMed.27853934.s19.e0" text="N-oxides" /></sentence><sentence text="" /><sentence text="Clinical DDI potential of specific CYP enzymes needs to be considered arising due to circulatory concentrations of certain N-oxides depending on the dose size and/or frequency of dosing of the respective parent drugs"><entity charOffset="123-131" id="DDI-PubMed.27853934.s21.e0" text="N-oxides" /></sentence><sentence text="" /></document>